https://de.marketscreener.com/kurs/aktie/HELIXMITH-CO-LTD-16561378/news/Helixmith-gibt-Topline-Ergebnisse-der-Phase-2A-Studie-mit-Engensis-zur-Behandlung-von-ALS-Amyotroph-41713408/?utm_source=telegram&utm_medium=social&utm_campaign=share